Beyond abiraterone: New hormonal therapies for metastatic castration-resistant prostate cancer

Cancer Biology and Therapy

Volumn 15, Issue 2, 2014, Pages 149-155

  Pinto, Alvaro ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Abiraterone; ARN 509; Castration resistant prostate cancer; Enzalutamide; Galeterone; ODM 201; Orteronel; TAK 700

Indexed keywords

ABIRATERONE; ARN-509; CASTRATION-RESISTANT PROSTATE CANCER; ENZALUTAMIDE; GALETERONE; ODM-201; ORTERONEL; TAK-700;

ANDROGEN ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONISTS; ANDROGENS; ANDROSTENOLS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84894543538     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.26724     Document Type: Review

References (65)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29; PMID: 22237781; http://dx.doi.org/10.3322/caac.20138
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917; PMID: 21351269; http://dx.doi.org/10.1002/ijc.25516
3. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079-92; PMID: 22424666; http://dx.doi.org/10.1016/j.eururo. 2012.02.054
4. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration- resistant prostate cancer. Eur Urol 2011; 59: 572-83; PMID: 21315502; http://dx.doi.org/10.1016/j. eururo.2011.01.025
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et al.; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12; PMID: 15470213; http://dx.doi.org/10. 1056/NEJMoa040720 (Pubitemid 39315317)
6. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-5; PMID: 18182665; http://dx.doi.org/10.1200/JCO.2007.12.4008
7. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20; PMID: 15470214; http://dx.doi.org/10. 1056/NEJMoa041318 (Pubitemid 39315318)
8. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, et al.; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration- resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54; PMID: 20888992; http://dx.doi.org/10.1016/S0140- 6736(10)61389-X
9. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr., Saad F, et al.; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005; PMID: 21612468; http://dx.doi.org/10.1056/NEJMoa1014618
10. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, et al.; COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebocontrolled phase 3 study. Lancet Oncol 2012; 13: 983-92; PMID: 22995653; http://dx.doi.org/10.1016/S1470-2045(12)70379-0
11. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza PL, Fizazi K, Mainwaring P, Piulats JM, Ng S, et al.; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-48; PMID: 23228172; http://dx.doi.org/10.1056/NEJMoa1209096
12. Rathkopf DE, Smith MR, De Bono JS, Logothetis C, Shore N, De Souza PL, et al. Long-term safety and efficacy analysis of abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer without prior chemotherapy (COU-AA-302). J Clin Oncol 2013; 31 :suppl; abstr 5009.
13. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009; 10: 981-91; PMID: 19796750; http://dx.doi.org/10.1016/S1470-2045(09) 70229-3
14. Massard C, Fizazi K. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 2011; 17: 3876-83; PMID: 21680543; http://dx.doi.org/10.1158/1078-0432.CCR-10-2815
15. Mohler JL. Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol 2008; 617: 223-34; PMID: 18497046; http://dx.doi.org/10.1007/978-0-387-69080-3-21
16. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815-25; PMID: 16510604; http://dx.doi.org/10.1158/0008-5472.CAN-05-4000
17. Mostaghel EA, Montgomery B, Nelson PS. Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol 2009; 27: 251-7; PMID: 19414113; http://dx.doi.org/10.1016/j.urolonc.2009.03.016
18. Nacusi LP, Tindall DJ. Androgen receptor abnormalities in castration-recurrent prostate cancer. Expert Rev Endocrinol Metab 2009; 4: 417-22; PMID: 20228873; http://dx.doi.org/10.1586/eem.09.34
19. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69: 16-22; PMID: 19117982; http://dx.doi.org/10.1158/ 0008-5472.CAN-08-2764
20. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-43; PMID: 22722839; http://dx.doi.org/10.1038/nature11125
21. Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008; 15: 841-9; PMID: 18667687; http://dx.doi.org/10.1677/ERC-08-0084
22. Lamont KR, Tindall DJ. Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol 2011; 25: 897-907; PMID: 21436259; http://dx.doi.org/10.1210/me.2010-0469
23. Schrecengost R, Knudsen KE. Molecular pathogenesis and progression of prostate cancer. Semin Oncol 2013; 40: 244-58; PMID: 23806491; http://dx.doi.org/10.1053/j.seminoncol.2013.04.001
24. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol 2007; 31: 1246-55; PMID: 17667550; http://dx.doi.org/10.1097/PAS.0b013e31802f5d33 (Pubitemid 47207130)
25. Anderson PD, McKissic SA, Logan M, Roh M, Franco OE, Wang J, Doubinskaia I, van der Meer R, Hayward SW, Eischen CM, et al. Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis. J Clin Invest 2012; 122: 1907-19; PMID: 22484818; http://dx.doi.org/10.1172/JCI58540
26. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA, Visakorpi T. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 2009; 69: 8141-9; PMID: 19808968; http://dx.doi.org/10.1158/0008-5472.CAN-09-0919
27. Donovan MJ, Osman I, Khan FM, Vengrenyuk Y, Capodieci P, Koscuiszka M, Anand A, Cordon-Cardo C, Costa J, Scher HI. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int 2010; 105: 462-7; PMID: 19624594; http://dx.doi.org/10.1111/j.1464-410X.2009.08747.x
28. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-43; PMID: 22722839; http://dx.doi.org/10.1038/nature11125
29. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68: 5469-77; PMID: 18593950; http://dx.doi.org/10.1158/0008-5472.CAN-08-0594
30. Chen S, Gulla S, Cai C, Balk SP. Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem 2012; 287: 8571-83; PMID: 22275373; http://dx.doi.org/10.1074/jbc. M111.325290
31. Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 2010; 21: 315-24; PMID: 20138542; http://dx.doi.org/10.1016/j.tem.2010.01.002
32. Augello MA, Hickey TE, Knudsen KE. FOXA1: master of steroid receptor function in cancer. EMBO J 2011; 30: 3885-94; PMID: 21934649; http://dx.doi.org/10.1038/emboj.2011.340
33. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, Sankila A, Turunen JP, Lundin M, Konsti J, et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J 2011; 30: 3962-76; PMID: 21915096; http://dx.doi.org/10.1038/emboj.2011.328
34. Gerhardt J, Montani M, Wild P, Beer M, Huber F, Hermanns T, Müntener M, Kristiansen G. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am J Pathol 2012; 180: 848-61; PMID: 22138582; http://dx.doi.org/10.1016/j.ajpath.2011.10. 021
35. Gallucci M, Merola R, Leonardo C, De Carli P, Farsetti A, Sentinelli S, Sperduti I, Mottolese M, Carlini P, Vico E, et al. Genetic profile identification in clinically localized prostate carcinoma. Urol Oncol 2009; 27: 502-8; PMID: 18534873; http://dx.doi.org/10.1016/j.urolonc.2008.04.008
36. Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis 2010; 13: 311-5; PMID: 20820186; http://dx.doi.org/10.1038/pcan.2010.31
37. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008; 68: 3584-90; PMID: 18483239; http://dx.doi.org/10.1158/0008-5472.CAN-07-6154
38. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A 2009; 106: 12465-70; PMID: 19592505; http://dx.doi.org/10.1073/pnas.0905931106
39. Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26: 4596-9; PMID: 17237811; http://dx.doi.org/10.1038/sj.onc.1210237 (Pubitemid 47037039)
40. Dumas L, Payne H, Chowdhury S. The evolution of antiandrogens: MDV3100 comes of age. Expert Rev Anticancer Ther 2012; 12: 131-3; PMID: 22316360; http://dx.doi.org/10.1586/era.11.210
41. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-90; PMID: 19359544; http://dx.doi.org/10.1126/science.1168175
42. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, et al.; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castrationresistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-46; PMID: 20398925; http://dx.doi.org/10.1016/S0140-6736(10)60172-9
43. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al.; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-97; PMID: 22894553; http://dx.doi.org/10.1056/NEJMoa1207506
44. Miller K, Scher HI, Fizazi K, Basch EM, Sternberg CN, Hirmand M, et al. Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration resistant prostate cancer (mCRPC) following docetaxel-based therapy: results from the AFFIRM study. J Clin Oncol 2013; 31:suppl 6; abstr 17.
45. Scher HI, Fizazi K, Saad Chi KN, Taplin ME, Sternberg CN, et al. Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide, an androgen receptor inhibitor. J Clin Oncol 2013; 31: suppl 6; abstr 6.
46. Golshayan AR, Antonarakis ES. Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. Core Evid 2013; 8: 27-35; PMID: 23589709
47. Smith MR, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A et al. Efficacy and safety of enzalutamide monotherapy in hormonenaïve prostate cancer. J Clin Oncol 2013;31: suppl; abstr 5001.
48. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012; 72: 1494-503; PMID: 22266222; http://dx.doi.org/10.1158/0008-5472.CAN-11-3948
49. Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, Arezzo JC, Powlin SS, Dinchuk JE, Balog A, et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 2011; 71: 480-8; PMID: 20878947; http://dx.doi.org/10.1002/pros.21263
50. Rathkopf DE, Danila DC, Morris MJ, Slovin SF, Steinbrecher JE, Arauz G et al. Phase I/II safety and pharmacokinetic study of ARN-509 in patients with metastatic castration-resistant prostate cancer patients: phase I results of a Prostate Cancer Clinical Trials Consortium study. J Clin Oncol 2012; 30: suppl 5; abstr 43.
51. Rathkopf DE, Antonarakis ES, Shore ND, Tutrone R, Alumkal JJ, Ryan CJ et al. ARN-509 in men with metastatic castration-resistant prostate cancer (mCPRC). J Clin Oncol 2013; 31: suppl 6; abstr 48.
52. Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore N, Liu G et al. ARN-509 in men with highrisk nonmetastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2013; 31:suppl 6; abstr 7.
53. Kaku T, Hitaka T, Ojida A, Matsunaga N, Adachi M, Tanaka T, Hara T, Yamaoka M, Kusaka M, Okuda T, et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem 2011; 19: 6383-99; PMID: 21978946; http://dx.doi.org/10.1016/j.bmc.2011.08.066
54. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011; 29: 3651-8; PMID: 21859989; http://dx.doi.org/10.1200/JCO.2011.35.2005
55. Agus DB, Stadler WM, Shevrin DH, Hart L, MacVicar GR, Hamid O et al. Safety, efficacy and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer: updated data form a phase I/II study. J Clin Oncol 2012; 30:suppl 5; abstr 98.
56. George DJ, Corn PG, Michaelson MD, Hammers HJ, Alumkal JJ, Ryan CJ et al. Safety and activity of the investigational agent orteronel without prednisone in men with nonmetastatic castration resistant prostate cancer and rising prostate-specific antigen: updated results of a phase II study. J Clin Oncol; 2012; X:suppl; abstr 4549.
57. Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, Brodie AM. Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3betahydroxy- 17- (1H-benzimidazole-1-yl)androsta- 5,16-diene in prostate cancer. Mol Cancer Ther 2008; 7: 2348-57; PMID: 18723482; http://dx.doi.org/10. 1158/1535-7163.MCT-08-0230
58. Montgomery RB, Eisenberger MA, Rettig M, Chu F, Pili R, Stephenson J et al. Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer. J Clin Oncol 2012; 30:suppl; abstr 4665.
59. Jacoby DB, Williams M. Differential effects of galeterone, abiraterone, orteronel and ketoconazole on CYP 17 and steroidogenesis. J Clin Oncol 2013; 3:suppl 6; abstr 184.
60. Massard C, James N, Culine S, Jones R, Vuorela A, Mustonen M, et al. ARADES trial: a first-in-man, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ODM-201 in patients with progressive metastatic castration resistant prostate cancer. Ann Oncol 2012; 23(suppl 9)
61. Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 2011; 60: 897-904; PMID: 21802835; http://dx.doi.org/10.1016/j.eururo.2011.07.011
62. Attard G, De Bono JS, Li W, Molina A, Griffin TW, San Kheoh T et al. ERG rearrangements and association with clinical outcome in patients receiving abiraterone acetate: Results from the COU-AA-302 study in chemotherapy- naïve metastatic castration- resistant prostate cancer. J Clin Oncol 2013; 31:suppl; abstr 5004.
63. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-9; PMID: 18829513; http://dx.doi.org/10. 1158/1078-0432.CCR-08-0872
64. Economos C, Morrissey C, Vessella RL. Circulating tumor cells as a marker of response: implications for determining treatment efficacy and evaluating new agents. Curr Opin Urol 2012; 22: 190-6; PMID: 22328019; http://dx.doi.org/10. 1097/MOU.0b013e3283519b58
65. Nakai Y, Nonomura N. Inflammation and prostate carcinogenesis. Int J Urol 2013; 20: 150-60; PMID: 22852773; http://dx.doi.org/10.1111/j.1442-2042.2012. 03101.x